1. Prevention of pulmonary vascular remodeling and of decreased BMPR-2 expression by losartan therapy in shunt-induced pulmonary hypertension
- Author
-
Ronald Van Beneden, Myriam Remmelink, Robert Naeije, Ives Hubloue, François Kerbaul, Pierre Fesler, Benoît Rondelet, Sandrine Huez, Isabelle Salmon, Serge Brimioulle, and Critical Care
- Subjects
medicine.medical_specialty ,Swine ,Physiology ,Hypertension, Pulmonary ,angiotensin II ,Pulmonary Artery ,Losartan ,Arteriovenous Shunt, Surgical ,left-to-right shunt ,bone morphogenetic protein ,Physiology (medical) ,Internal medicine ,medicine ,Animals ,Lung ,Antihypertensive Agents ,Angiotensin II receptor type 1 ,Endothelin-1 ,Neovascularization, Pathologic ,business.industry ,angiopoietin ,Respiratory disease ,medicine.disease ,Angiotensin II ,Pulmonary hypertension ,Treatment Outcome ,medicine.anatomical_structure ,Endocrinology ,Gene Expression Regulation ,Circulatory system ,cardiovascular system ,Vascular resistance ,Pulmonar vascular remodeling ,Cardiology and Cardiovascular Medicine ,business ,hormones, hormone substitutes, and hormone antagonists ,circulatory and respiratory physiology ,medicine.drug - Abstract
The renin-ANG system has been reported to be overexpressed in pulmonary arterial hypertension (PAH). We investigated the effects of ANG receptor-1 blockade by losartan on hemodynamics and signaling molecules in a piglet overflow model of early PAH. Twenty-six 3-wk-old piglets were randomized to placebo or losartan therapy (1 mg·kg−1·day−1) after anastomosis of the inominate to the main pulmonary artery or after a sham operation. Three months later, the animals underwent a hemodynamic evaluation, followed by pulmonary tissue sampling for morphometry, immunohistochemistry, and real-time quantitative-PCR. Chronic systemic-to-pulmonary shunting increased the pulmonary vascular resistance from 2.5 ± 0.2 to 6.2 ± 0.3 mmHg·l−1·min·m−2and arteriolar medial thickness from 13.6 to 25.4%. These changes were associated with increased expressions of ANG II and its type 1 (AT1) and type 2 (AT2) receptors, endothelin-1 (ET-1) and its type B receptor (ETB), and angiopoietin-1, together with decreased expressions of bone morphogeneic protein receptor-1A and -2 (BMPR-1A and BMPR-2, respectively) and unchanged expression of the receptor tyrosine kinase with immunoglobulin and EGF homology domains-2 (Tie 2). Pretreatment with losartan decreased shunt-induced pulmonary vascular resistance and medial thickness by 51% and 35%, respectively. Losartan therapy was associated with persistent overexpressions of ANG II, AT2, ET-1, ETB, and angiopoietin-1 and with a return to normal of the BMPR-2 expression. These results suggest that ANG II contributes to left-to-right, shunt-induced PAH.
- Published
- 2005
- Full Text
- View/download PDF